Travere Therapeutics Q1 2024 Adj EPS $(1.51) Misses $(0.99) Estimate, Sales $41.374M Miss $42.847M Estimate
Travere Therapeutics Q1 2024 Adj EPS $(1.51) Misses $(0.99) Estimate, Sales $41.374M Miss $42.847M Estimate
Travere Therapeutics 2024年第一季度调整后每股收益美元（1.51）未达到预期（0.99 美元），销售额为4137.4万美元，低于4284.7万美元的预期
Travere Therapeutics (NASDAQ:TVTX) reported quarterly losses of $(1.51) per share which missed the analyst consensus estimate of $(0.99) by 52.53 percent. This is a 64.13 percent decrease over losses of $(0.92) per share from the same period last year. The company reported quarterly sales of $41.374 million which missed the analyst consensus estimate of $42.847 million by 3.44 percent. This is a 33.95 percent increase over sales of $30.888 million the same period last year.
Travere Therapeutics（纳斯达克股票代码：TVTX）公布的季度亏损为每股1.51美元（1.51美元），比分析师普遍预期的0.99美元（0.99美元）低52.53％。与去年同期每股亏损0.92美元（0.92）相比，下降了64.13％。该公司公布的季度销售额为4137.4万美元，比分析师普遍预期的4284.7万美元低3.44％。这比去年同期的3,0888万美元的销售额增长了33.95％。